Detalhe da pesquisa
1.
Minimally Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment: A New Concept.
Ann Surg Oncol
; 31(2): 957-965, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37947974
2.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36056374
3.
Diagnosing Pathologic Complete Response in the Breast After Neoadjuvant Systemic Treatment of Breast Cancer Patients by Minimal Invasive Biopsy: Oral Presentation at the San Antonio Breast Cancer Symposium on Friday, December 13, 2019, Program Number GS5-03.
Ann Surg
; 275(3): 576-581, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32657944
4.
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
Int J Cancer
; 146(1): 262-271, 2020 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31162838
5.
ASO Visual Abstract: Minimally-Invasive Breast Biopsy After Neoadjuvant Systemic Treatment to Identify Breast Cancer Patients with Residual Disease for Extended Neoadjuvant Treatment-A New Concept.
Ann Surg Oncol
; 31(2): 1033-1034, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38093166
6.
RESPONDER - diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast Cancer - a multicenter, confirmative, one-armed, intra-individually-controlled, open, diagnostic trial.
BMC Cancer
; 18(1): 851, 2018 Aug 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30144818
7.
Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69).
Breast Cancer Res Treat
; 163(3): 495-506, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28315068
8.
Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial.
Lancet Oncol
; 17(3): 345-356, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26869049
9.
A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
Cancer
; 121(20): 3639-48, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26111104
10.
A systematic and sensitive method for critical reagent antibody evaluation with PCA technology.
Bioanalysis
; 14(23): 1479-1486, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36799240
11.
Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery.
J Clin Oncol
; 40(17): 1903-1915, 2022 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35108029
12.
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
Clin Cancer Res
; 28(22): 4995-5003, 2022 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35797219
13.
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
J Immunother Cancer
; 9(5)2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33963012
14.
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
Eur J Cancer
; 148: 159-170, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743484
15.
NAB-Paclitaxel Improves Disease-Free Survival in Early Breast Cancer: GBG 69-GeparSepto.
J Clin Oncol
; 37(25): 2226-2234, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31082269
16.
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
J Natl Cancer Inst
; 110(6): 628-637, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29228315